

Special Issue

COVID-19 Vaccine Acceptance: Ethical, Legal and Social Aspects (ELSA)

Message from the Guest Editor

Despite its relatively high accessibility and low burden of adherence, and despite the significant progress in science, efficacy, safety, and healthcare planning, as well as its established success, the acceptance of vaccination, especially COVID-19 vaccination, has been especially challenging. Vaccine acceptance has received increasing attention over the last two decades. As challenges to vaccine acceptance have arisen, there have also been significant changes in cultural and social climates, the communication landscape, political polarization, and the environment that may contribute to this challenge. In this Special Issue, we invite academic reflections on vaccine acceptance, insights from a broad range of disciplines that target diverse factors that may be related to vaccine acceptance, and interventions that may show promise to address these challenges that particularly focus on the roles of cultural, social, political, and ethical interests. Dr. Rachael N. Piltch-Loeb

Guest Editor

Dr. Rachael N. Piltch-Loeb

Department of Biostatistics, Harvard TH Chan School of Public Health, Boston, MA, USA

Deadline for manuscript submissions

closed (1 September 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/118497

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).